MA40791A - Ciblage lysosomal d'enzymes et utilisations associées - Google Patents

Ciblage lysosomal d'enzymes et utilisations associées

Info

Publication number
MA40791A
MA40791A MA040791A MA40791A MA40791A MA 40791 A MA40791 A MA 40791A MA 040791 A MA040791 A MA 040791A MA 40791 A MA40791 A MA 40791A MA 40791 A MA40791 A MA 40791A
Authority
MA
Morocco
Prior art keywords
enzymes
lysosomal targeting
lysosomal
related uses
compositions
Prior art date
Application number
MA040791A
Other languages
English (en)
Inventor
Michael F Concino
Bohong Zhang
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of MA40791A publication Critical patent/MA40791A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Abstract

L'invention fournit des compositions et des procédés pour un ciblage lysosomal efficace médié par pcsk9. En particulier, les compositions et les procédés fournis par l'invention peuvent être utilisés pour traiter des maladies de stockage lysosomales telles que pompe disease et sanfilippo syndrome type b, et ils peuvent être utilisés pour cibler des enzymes lysosomales sur les différents muscles du corps humain.
MA040791A 2014-10-24 2015-10-23 Ciblage lysosomal d'enzymes et utilisations associées MA40791A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462068033P 2014-10-24 2014-10-24

Publications (1)

Publication Number Publication Date
MA40791A true MA40791A (fr) 2017-09-27

Family

ID=54478975

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040791A MA40791A (fr) 2014-10-24 2015-10-23 Ciblage lysosomal d'enzymes et utilisations associées

Country Status (4)

Country Link
US (1) US10556015B2 (fr)
EP (1) EP3220958A1 (fr)
MA (1) MA40791A (fr)
WO (1) WO2016065319A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220133863A1 (en) * 2010-06-25 2022-05-05 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
AU2016365834B2 (en) * 2015-12-08 2023-09-28 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
KR20240001721A (ko) 2016-09-12 2024-01-03 제네똥 산-알파 글루코시다제 변이체 및 이의 용도
EP3293203A1 (fr) * 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
EP3293259A1 (fr) * 2016-09-12 2018-03-14 Genethon Variants d'alpha-glucosidase acide et leurs utilisations
CA3066569A1 (fr) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions et methodes pour l'internalisation d'enzymes
US20200206323A1 (en) * 2017-09-08 2020-07-02 The Nemours Foundation An agent, a device and a blood-circulation system for treating lysosomal storage diseases, and a method for treating lysosomal storage diseases
EP3787748A1 (fr) * 2018-05-01 2021-03-10 OrfoNeuro ApS Traitement de la céroïde-lipofuscinose neuronale

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003102583A1 (fr) 2002-05-29 2003-12-11 Symbiontics, Inc. Proteines therapeutiques ciblees
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
EP1716232B9 (fr) * 2004-02-10 2010-10-13 ZyStor Therapeutics , Inc. Alpha-glucosidase acide et fragments de celle-ci
WO2007128121A1 (fr) * 2006-05-08 2007-11-15 Adaerata, Limited Partnership Protéines pcsk9 chimériques, cellules les comprenant et dosages les utilisant
HUE034850T2 (en) 2008-05-07 2018-03-28 Biomarin Pharm Inc Lysosomal targeting peptides and their use
EP3679942A1 (fr) 2009-06-17 2020-07-15 BioMarin Pharmaceutical Inc. Formulations pour des enzymes lysosomales
ES2643015T3 (es) * 2010-06-25 2017-11-21 Shire Human Genetic Therapies, Inc. Tratamiento del Síndrome de Sanfilippo Tipo B
EP2471929A1 (fr) * 2010-12-29 2012-07-04 Algenics Production de protéines glycosylées à forte teneur en mannose stockées dans les plastides de micro-algues
AU2013352184B2 (en) 2012-11-27 2018-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof

Also Published As

Publication number Publication date
EP3220958A1 (fr) 2017-09-27
US20170333569A1 (en) 2017-11-23
WO2016065319A1 (fr) 2016-04-28
US10556015B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
PH12017501481B1 (en) Bicyclic heterocycles as fgfr inhibitors
PH12017501611A1 (en) Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
EA201891674A1 (ru) Ингибиторы лизилоксидаз, представляющие собой индольные и азаиндольные производные галогеналлиламина, и их применения
MA35023B1 (fr) Inhibiteurs de la glucosylcéramide synthase
EA202091709A1 (ru) Ингибиторы днк-пк
EA201400625A1 (ru) Антитела против pd-l1 и их применение
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
AU2012253757A8 (en) Partially saturated tricyclic compounds and methods of making and using same
MX2022016427A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
RS53467B (en) USE OF AMISULPRID FOR TREATMENT OF Nausea and Vomiting Caused by Chemotherapy
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA202091708A1 (ru) Ингибиторы днк-пк
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
MX2022005132A (es) Terapia combinada con formulaciones de anticuerpos anti-pvrig y anticuerpos anti-pd-1.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
EA201791845A1 (ru) Твердые формы менахинолов
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
WO2019043176A3 (fr) Inhibiteur de l'histone-désacétylase en association avec un agent antimétabolite pour la cancérothérapie